Boya Biotech: Announcement of Resolutions of the 22nd Meeting of the Company’s Eighth Board of Directors
Securities code: 300294 Securities abbreviation: Boya Biotechnology Announcement number: 2026-050
China Resources Boya Biopharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 22nd Meeting of the Eighth Board of Directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The 22nd meeting of the eighth board of directors of China Resources Boya Biopharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") was notified by email and communication on August 10, 2026, and was held on August 20, 2026 in the company's conference room by on-site and communication voting. Nine people were supposed to be present at the meeting, but nine people actually showed up. The meeting was chaired by Chairman Qiu Kai, and senior managers of the company attended the meeting. This meeting complied with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and the "Articles of Association" and other relevant regulations. After full discussion, the following motions were reviewed and approved.
2. Review status of board of directors meeting
(1) Consideration and approval of the “Proposal on the Full Text and Summary of the Company’s 2026 Semi-annual Report”
After review, the board of directors believes that the "Full Text and Summary of the 2026 Semi-Annual Report" prepared by the company truly, accurately and completely reflects the company's financial status and operating results for the first half of 2026, and there are no false records, misleading statements or major omissions.
This proposal was reviewed and approved at the 18th meeting of the Audit Committee of the eighth session of the Board of Directors before being submitted to the Board of Directors for review, and the Audit Committee of the Board of Directors issued a clear approval review opinion.
For details, please refer to the "Company's 2026 Semi-Annual Report" and "Company's 2026 Semi-Annual Report Summary" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
(2) Deliberating and approving the “Proposal on the Progress of the “Double Improvement of Quality and Return” Action Plan”
In order to thoroughly implement the spirit of the Political Bureau Meeting of the Central Committee and the Executive Meeting of the State Council on promoting high-quality development of the real economy, continue to improve the quality and efficiency of the company's operation and management, further build core competitiveness, and strengthen the company's profitability and comprehensive risk management and control capabilities, the company attaches great importance to relevant work arrangements and makes solid progress. Based on relevant requirements, we are now conducting a comprehensive review and evaluation of the implementation progress of the action plan from January to June 2026.
For details, please refer to the "Company's Announcement on the Progress of the "Double Improvement of Quality and Return" Action Plan" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
(3) Consider and approve the “Proposal on the Special Report on the Deposit and Use of Funds Raised by the Company in the Half-Year of 2026”
After deliberation, the board of directors believes that: the company's deposit and use of raised funds in the 2026 half-year are in compliance with the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange on the storage and use of raised funds by listed companies. There are no violations in the storage and use of raised funds, and there are no disguised changes in the investment direction of raised funds and damage to the interests of shareholders; the content of the company's "Special Report on the Deposit and Use of Raised Funds in the Half-Year 2026" is true, accurate and complete, and there are no false records, misleading statements or major omissions.
This proposal was reviewed and approved at the 18th meeting of the Audit Committee of the 8th Board of Directors of the Company before being submitted to the Board of Directors for review.
For details, please refer to the "Special Report on the Storage and Use of Funds Raised in the Half Year of 2026" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
(4) Consideration and approval of the “Proposal on the by-election of independent directors of the eighth session of the Board of Directors”
After deliberation, the board of directors believes that the company's board of directors' by-election of Feng Sizhou and Lin Ang as independent director candidates for the eighth board of directors complies with the provisions of the Company Law, Securities Law, Articles of Association and other laws and regulations. This proposal was reviewed and approved by the Nomination, Remuneration and Appraisal Committee of the eighth session of the Board of Directors at the 15th meeting before being submitted to the Board of Directors for review. The Nomination, Remuneration and Appraisal Committee of the Board of Directors issued clear approval review opinions.
For details, please refer to the "Company's Announcement on the Resignation of Independent Directors and the By-Election of Independent Directors and Members of Special Committees" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, 0 abstentions
After full discussion, the following sub-proposals were voted on item by item:
4.1 Proposal on the by-election of Feng Sizhou as an independent director of the company
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
4.2 Proposal on the by-election of Lin Ang as the company’s independent director
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
This proposal still needs to be submitted to the company's second extraordinary shareholders' meeting in 2026 for review.
(5) Consideration and approval of the "Proposal on the by-election of members of the special committees of the eighth session of the Board of Directors"
For details, please refer to the "Company's Announcement on the Resignation of Independent Directors and the By-Election of Independent Directors and Members of Special Committees" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day.
Voting results: 9 votes in favor, 0 votes against, 0 abstentions
After full discussion, the following sub-proposals were voted on item by item:
5.1 Proposal on by-election of members of the Strategy and ESG Committee of the Eighth Board of Directors
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
5.2 Proposal on by-election of members of the Audit Committee of the eighth session of the Board of Directors
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
The conditions for the establishment and effectiveness of the "Proposal on the by-election of members of the special committees of the eighth session of the Board of Directors" are that the above-mentioned "Proposal on the by-election of independent directors of the eighth session of the Board of Directors" is reviewed and approved by the company's shareholders' meeting.
(6) Consideration and approval of the “Proposal on Further Optimizing the Company’s Organizational Structure”
In view that the company has transferred 100% of its equity in Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Shuanghe Pharmaceutical Co., Ltd., and Green Cross (China) Biological Products Co., Ltd. has been renamed China Resources Boya Biopharmaceutical (Anhui) Co., Ltd., in order to adapt to the changes in the company's equity layout, strategic integration and business development needs, the company has adjusted its organizational structure.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
(7) Consider and approve the “Proposal on the Company’s Total Salary Budget Plan for 2026”
In order to consolidate the rigid management and control responsibilities of the salary budget, standardize the closed-loop management of the entire salary process, combine the relevant national policy control requirements and the current downward development situation of the industry, and anchor the company's annual business development plan, the "2026 Total Salary Budget Plan" is specially formulated.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
(8) The "Proposal on Proposing to Convene the Company's Second Extraordinary Shareholders' Meeting in 2026" was reviewed and approved. The company plans to hold the company's second extraordinary shareholders' meeting in 2026 at 14:00 pm on September 10, 2026 in the company conference room on the 15th floor of Kerry Hongchuang Development Center, No. 138 Shimao Road, Honggutan District, Nanchang City, Jiangxi Province. The equity registration date is September 3, 2026. The following proposals will be considered:
Serial number Bill name
1.00 "Proposal on the by-election of independent directors of the eighth session of the Board of Directors" 1.01 Proposal on the by-election of Feng Sizhou as the company's independent director
1.02 Proposal on the by-election of Lin Ang as the company’s independent director
For details, please refer to the "Company's Notice on Convening the Second Extraordinary Shareholders' Meeting in 2026" disclosed on the cninfo.com (website: http://www.cninfo.com.cn) on the same day. Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
3. Documents for reference
- Resolution of the 22nd meeting of the company’s eighth board of directors.
Announcement is hereby made.
Board of Directors of China Resources Boya Biopharmaceutical Group Co., Ltd.
August 22, 2026